

## Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males

Chiara Fallerini, PhD<sup>1,2,\*</sup>, Sergio Daga, PhD<sup>1,2,\*</sup>, Stefania Mantovani, MSc<sup>3,\*</sup>, Elisa Benetti, MS<sup>2</sup>, Aurora Pujol, MD, PhD<sup>4,5,6</sup>, Nicola Picchiotti, MS<sup>7,8</sup>, Agatha Schluter PhD<sup>4,5</sup>, Laura Planas-Serra MSc<sup>4,5</sup>, Jesús Troya MD<sup>9</sup>, Margherita Baldassarri, MD<sup>1,2</sup>, Francesca Fava, MD<sup>1,2,10</sup>, Serena Ludovisi, MD<sup>3,11</sup>, Francesco Castelli, MD<sup>12</sup>, Maria Eugenia Quiros-Roldan<sup>12</sup>, Massimo Vaghi<sup>13</sup>, Stefano Rusconi<sup>14,15</sup>, Matteo Siano<sup>15</sup>, Maria Bandini<sup>16</sup>, Simone Furini, PhD<sup>2</sup>, Francesca Mari, MD PhD<sup>1,2,9</sup>, GEN-COVID Multicenter Study, Alessandra Renieri, MD, PhD<sup>1,2,10,^</sup>, Mario U. Mondelli, MD PhD<sup>3,11,\$</sup>, Elisa Frullanti, PhD<sup>1,2,\$</sup>

- 1) Medical Genetics, University of Siena, Italy
- 2) Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy
- 3) Division of Infectious Diseases and Immunology, Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 4) Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
- 5) CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, ISCIII, Madrid, Spain
- 6) Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
- 7) Department of Mathematics, University of Pavia, Pavia, Italy
- 8) University of Siena, DIISM-SAILAB, Siena, Italy
- 9) Infanta Leonor University Hospital, Madrid, Spain
- 10) Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy
- 11) Department of Internal Medicine and Therapeutics, University of Pavia, Italy
- 12) Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy
- 13) Chirurgia Vascolare, Ospedale Maggiore di Crema, Italy
- 14) III Infectious Diseases Unit, ASST-FBF-Sacco, Milan, Italy
- 15) Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
- 16) Department of Preventive Medicine, Azienda USL Toscana Sud Est, Italy

\* **Co-first author**

\$ **Co-last author**

^ **Corresponding author:**

Professor Alessandra Renieri  
 Medical Genetics Unit  
 University of Siena  
 Policlinico Le Scotte  
 Viale Bracci, 2, 53100 Siena, Italy  
 Phone: +39 0577 233303  
 Fax: +39 0577 233325  
 E.mail: [alessandra.renieri@unisi.it](mailto:alessandra.renieri@unisi.it)

**Funding Statement:** We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) <http://www.nig.cineca.it> for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). We also thank the COVID-19 Host Genetics Initiative (<https://www.covid19hg.org/>); MIUR project “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy. We also thank Intesa San Paolo for the 2020 charity fund dedicated to the project N. B/2020/0119 “Identificazione delle basi genetiche determinanti la variabilità clinica della risposta a COVID-19 nella popolazione italiana”.

**Disclosure Statement:** The authors declare no competing interests.

## ABSTRACT

**Background:** COVID-19 clinical presentation ranges from asymptomatic to fatal outcome. This variability is due in part to host genome specific mutations. Recently, two families in which COVID-19 segregates like an X-linked recessive monogenic disorder environmentally conditioned by SARS-CoV-2 have been reported leading to identification of loss-of-function variants in *TLR7*.

**Objective:** We sought to determine whether the two families represent the tip of the iceberg of a subset of COVID-19 male patients.

**Methods:** We compared male subjects with extreme phenotype selected from the Italian GEN-COVID cohort of 1178 SARS-CoV-2-infected subjects (<60y, 79 severe cases versus 77 control cases). We applied the LASSO Logistic Regression analysis, considering only rare variants on the young male subset, picking up *TLR7* as the most important susceptibility gene.

**Results:** Rare *TLR7* missense variants were predicted to impact on protein function in severely affected males and in none of the asymptomatic subjects. We then investigated a similar white European cohort in Spain, confirming the impact of *TLR7* variants. A gene expression profile analysis in peripheral blood mononuclear cells after stimulation with TLR7 agonist demonstrated a reduction of mRNA level of TLR7, IRF7, ISG15, IFN- $\alpha$  and IFN- $\gamma$  in COVID-19 patients compared with unaffected controls demonstrating an impairment in type I and II INF responses.

**Conclusion:** Young males with *TLR7* loss-of-function mutations and severe COVID-19 in the two reported families represent only a fraction of a broader and complex host genome situation. Specifically, missense mutations in the X-linked recessive *TLR7* disorder may significantly contribute to disease susceptibility in up to 4% of severe COVID-19.

**Clinical Implication:** In this new yet complex scenario, our observations provide the basis for a personalized interferon-based therapy in patients with rare *TLR7* variants.

## CAPSULE SUMMARY

Our results in large cohorts from Italy and Spain showed that X-linked recessive TLR7 disorder may represent the cause of disease susceptibility to COVID-19 in up to 4% of severely affected young male cases.

**Key Words:** TLR7, COVID-19, LASSO Logistic Regression analysis

## Abbreviations

Ala: Alanine amino acid

Asp: Asparagine amino acid

CADD: Combined Annotation Dependent Depletion

COVID-19: COronaVirus Disease 19

His: Histidine amino acid

HPRT1: hypoxanthine phosphoribosyltransferase 1

INFs: Interferons

IFN- $\alpha$ : Interferon Alpha

IFN- $\beta$ 1: Interferon Beta1

IFN- $\gamma$ : Interferon Gamma

IL-1: Interleukin 1

IL-6: Interleukin 6

Ile: Isoleucine amino acid

IRF7: Interferon Regulatory Factor 7

ISG15: Interferon-Stimulated Gene 15

LASSO: Least Absolute Shrinkage and Selection Operator

LBP: LipoPolySaccharide (LPS) Binding Protein

NIG: Network of Italian Genome

PBMCs: Peripheral Blood Mononuclear Cells

Pro: Proline amino acid

RNA: RiboNucleic Acid

Ser: Serine amino acid

SARS-CoV-2: Severe Acute Respiratory Syndrome caused by CoronaVirus

Thr: Threonine amino acid

TLRs: Toll-like Receptors

TLR4: Toll-like Receptor 4

TLR7: Toll-like Receptor 7

TNF- $\alpha$ : Tumor Necrosis Factor  $\alpha$

Tyr: Tyrosine amino acid

Val: Valine amino acid

WES: Whole Exome Sequencing

## INTRODUCTION

Coronavirus disease 2019 (COVID-19), a potentially severe systemic disease caused by coronavirus SARS-CoV-2, is characterized by a highly heterogeneous phenotypic variability, with the large majority of infected individuals experiencing only mild or even no symptoms. However, severe cases can rapidly evolve towards a critical respiratory distress syndrome and multiple organ failure<sup>1</sup>. COVID-19 still represents an enormous challenge for the world's healthcare systems ten months after the first appearance in December 2019 in Wuhan, Huanan, Hubei Province of China. Symptoms of COVID-19 range from fever, cough, sore throat, congestion, anosmia and fatigue to shortness of breath, interstitial pneumonia followed by respiratory distress and septic shock<sup>1</sup>. Although older age and the presence of cardiovascular or metabolic comorbidities have been identified as risk factors predisposing to severe disease<sup>2</sup>, these factors alone do not fully explain the differences in the severity. Male patients show more severe clinical manifestations than females with higher prevalence of hospitalizations (16% versus 12%), ICU admissions (3% versus 2%), and deaths (6% versus 5%), indicating that gender may influence the outcome of the disease<sup>3</sup>. These findings suggest a role of host predisposing genetic factors in the pathogenesis of the disease which may be responsible for different clinical outcomes as a result of different antiviral defence mechanisms as well as specific receptor permissiveness to virus and immunogenicity.

More than that, recent evidences suggest also a fundamental role of IFN genes in genetic bases of COVID-19; in particular, recently rare variants have been identified in the interferon type I pathway that are responsible for inborn errors of immunity in a small percentage of patients and auto-antibodies against type I interferon genes in up to 10% of severe COVID-19 cases<sup>4,5</sup>.

Toll-like receptors (TLRs) are crucial components in the initiation of innate immune response - the non specific-immune response- to a variety of pathogens, causing the production of pro-inflammatory cytokines (TNF- $\alpha$ , IL-1, and IL-6) and type I and II IFNs, that are responsible for innate antiviral responses. In particular the innate immune response is very sensitive in detecting potentially pathogenic antigens, activating downstream signaling to induce transcription

factors in the nucleus, promoting synthesis and release of types I and type III interferons (IFNs) in addition to a number of other important proinflammatory cytokines. However, when the immune response is dysregulated, it can result in excessive inflammation, or in extreme cases, death. Among them, TLR7 recognises several single-stranded RNA viruses including SARS-CoV-2<sup>6</sup>. We previously showed that another RNA virus, hepatitis C virus (HCV), is able to inhibit CD4 T cell function via Toll-like receptor 7 (TLR7)<sup>7</sup>. Recently, van der Made *et al.* have reported two independent families in which COVID-19 segregates like an X-linked recessive monogenic disorder conditioned by SARS-CoV-2, as an environmental factor<sup>8</sup>.

Here, we performed a nested case-control study (NCC) within our prospectively recruited GEN-COVID cohort with the aim to determine whether the 2 families described by van der Made *et al.* represent an ultra-rare situation or the tip of the iceberg of a larger subset of young male patients.

## RESULTS AND DISCUSSION

We applied LASSO logistic regression analysis, after correcting for Principal Components, to a synthetic boolean representation of the entire set of genes of the X chromosome on the extreme phenotypic ends of the young male subset of the Italian GEN-COVID cohort (<https://sites.google.com/dbm.unisi.it/gen-covid>)<sup>9</sup>. Cases were selected according to the following inclusion criteria: *i.* male gender; *ii.* young age (<60 years); *iii.* endotracheal intubation or CPAP/biPAP ventilation (79 subjects). As controls, 77 subjects were selected using the sole criterion of being oligo-asymptomatic not requiring hospitalization. Cases and controls represented the extreme phenotypic presentations of the GEN-COVID cohort. Exclusion criteria for both cases and controls were: *i.* SARS-CoV-2 infection not confirmed by PCR; *ii.* non-caucasian ethnicity. The materials and methods details are listed in the Online Repository section.

The study (GEN-COVID) was consistent with Institutional guidelines and approved by the University Hospital (Azienda Ospedaliero-Universitaria Senese) Ethical Review Board, Siena, Italy (Prot n. 16929, dated March 16, 2020). Only rare variants ( $\leq 1\%$  in European Non-Finnish

population) were considered in the boolean representation: the gene was set to 1 if it included at least a missense, splicing, or loss of function rare variant, and 0 otherwise. Fisher Exact test was then used for the specific data validation.

Toll-like receptor 7 (*TLR7*) was picked up as one of the most important susceptibility genes by LASSO Logistic Regression analysis (**Figure 1**). We then queried the COVID-19 section of the Network of Italian Genome NIG database (<http://www.nig.cineca.it/>, specifically, <http://nigdb.cineca.it>) that houses the entire GEN-COVID cohort represented by more than 1000 WES data of COVID-19 patients and SARS-CoV-2 infected asymptomatic subjects<sup>7</sup>. By selecting for young (<60 year-old) males, we obtained rare ( $MAF \leq 1\%$ ) *TLR7* missense variants predicted to impact on protein function ( $CADD > 12.28$ ) in 5 out of 79 male patients (6,32%) with life-threatening COVID-19 (hospitalized intubated and hospitalized CPAP/BiPAP) and in none of the 77 SARS-CoV2 infected oligo-asymptomatic male subjects.

A similar Spanish cohort, composed of male patients under 60 years of age without comorbidities (77 cases and 45 controls) was used to expand the cohort to another representative European population highly impacted by COVID-19. All subjects were white European. The Spanish Covid HGE cohort is under IRB approval PR127/20 from Bellvitge University Hospital, Barcelona, Spain. We found a *TLR7* variant in one of 77 cases (1,29%) and in none of 45 controls. Overall, the association between the presence of *TLR7* rare mutations and severe COVID-19 was significant ( $p = 0.04$  by Fisher Exact test, **Table 1**).

We then investigated the presence of *TLR7* mutations in the entire male cohort of COVID-19 (cases and controls) regardless of age. We found *TLR7* rare missense variants in 3 additional patients over 60 years of age, including 2 among cases and 1 among controls, the last bearing the mutation p.Val222Asp predicted to have a low impact on protein function ( $CADD$  of 5.36) (**Table 2**).

In order to functionally link the presence of the identified *TLR7* missense mutations and the effect on the downstream type I IFN-signaling, we performed a gene expression profile analysis in peripheral blood mononuclear cells (PBMCs) isolated from patients after stimulation

with the TLR7 agonist imiquimod (as reported by van der Made *et al.*<sup>8</sup>). PBMCs from 5 out of 8 cases and from the control were available. All *TLR7* variants were tested except one (Ala288Val) as some different patients share the same. This analysis showed a statistically significant decrease of *IRF7* (member of the interferon regulatory transcription factor) and *IFN- $\gamma$*  mRNA levels in all tested mutations (Val219Ile, Ser301Pro, Ala1032Thr, His630Tyr) identified in cases (P1, P3, P7, P8 and P6) compared with healthy (Ctl) demonstrating a complete impairment in IFN- $\alpha$  and IFN- $\gamma$  production in response to TLR7 stimulation in all patients (**Figure 2**). A similarly significant reduction was shown for ISG15 (Interferon-stimulated gene 15) and *IFN- $\alpha$*  mRNA level for 4 out of 5 patients (P3, P8, P6, P7). An analogous trend was observed for TLR7 in P8 and P6 cases. A significant reduction was also shown for all TLR7-related mRNA transcripts when cases were compared with the asymptomatic controls (C1) (**Supplementary Figure 1**). Interestingly, the p.Val222Asp variant proved to be functionally neutral in keeping with its discovery in control and not in cases (**Figure 2**). TLR7 expression was evaluated in monocytes and B cells from patients and healthy controls by flow cytometry. As shown in **Supplementary Figure 2** patients and controls expressed the TLR7 protein at intracellular level. The functional capacity of PBMC was evaluated after stimulation with the TLR4 agonist lipopolysaccharide (LPS). The analysis showed that LPS-induced production of IL6 by CD3-CD14<sup>+</sup> cells was similar in patients and controls (**Supplementary Figure 3**).

Segregation analysis was available for two of 8 cases, P3 and P6 (**Figure 3**). In both pedigree, the disease nicely segregates as an X-linked disorder conditioned by environmental factors, i.e. SARS-Cov-2 (**Figure 3, panel B**). This was also supported by functional analysis on all *TLR7*-related genes (**Supplementary Figure 4**). As an example, we showed gene expression profile analysis for *IRF7* gene: in male patients *IRF7* mRNA levels are statistically significantly reduced compared to heterozygous females (**Figure 3, panel A**). Of note, only the infected mutated male subject had severe COVID-19, whereas the infected not mutated female (sister) was oligosymptomatic with symptoms lasting 7-10 days; the infected mutated female (one of the



daughters) was oligosymptomatic with symptoms lasting one month (**Figure 3, panel C**). Both females did not require any hospital treatment.

Our results showed that the two families with loss of function mutations reported by van der Made *et al.*<sup>8</sup> in males with severe COVID-19 with a mean age of 26 years are indeed the tip of the iceberg of a broader host genome scenario. Specifically, missense mutations in the X-linked recessive TLR7 disorder may represent the cause of disease susceptibility to COVID-19 in up to 4% of severely affected young male cases (6/156, 3,84%). Since not all identified mutations were functionally tested, the true percentage could be slightly lower. Overall, males with missense mutations shown here developed COVID-19 at a mean age of 58 years, considerably later than 26 years, in agreement with a predicted smaller impact on the protein than the loss of function mutations reported by van der Made *et al.*<sup>8</sup>. Similarly, the identified rare missense *TLR7* variants impaired the mRNA expression of *TLR7* as well as the downstream pathway. The observation reported here may lead to consider *TLR7* screening in severely affected male patients in order to start personalized interferon treatment for those with this specific genetic disorder.

## ACKNOWLEDGEMENTS

This study is part of the GEN-COVID Multicenter Study, <https://sites.google.com/dbm.unisi.it/gen-covid>, the Italian multicenter study aimed at identifying the COVID-19 host genetic bases. Specimens were provided by the COVID-19 Biobank of Siena, which is part of the Genetic Biobank of Siena, member of BBMRI-IT, of Telethon Network of Genetic Biobanks (project no. GTB18001), of EuroBioBank, and of D-Connect. We thank the CINECA consortium for providing computational resources and the Network for Italian Genomes (NIG) <http://www.nig.cineca.it> for its support. We thank private donors for the support provided to A.R. (Department of Medical Biotechnologies, University of Siena) for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). We also thank the COVID-19 Host Genetics Initiative (<https://www.covid19hg.org/>). MIUR project “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy. Research on



the Spanish cohort received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 824110 – EASI-Genomics, to AP.

## REFERENCES (max 25)

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 February 24. doi: 10.1001/jama.2020.2648.
2. Hägg S, Jylhävä J, Wang Y, Xu H, Metzner C, Annetorp M, et al. Age, Frailty, and Comorbidity as Prognostic Factors for Short-Term Outcomes in Patients With Coronavirus Disease 2019 in Geriatric Care. *J Am Med Dir Assoc*. 2020 Aug 14:S1525-8610(20)30704-0. doi: 10.1016/j.jamda.2020.08.014.
3. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:759-65.
4. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science*. 2020 Sep 24:eabd4570. doi: 10.1126/science.abd4570. Epub ahead of print. PMID: 32972995.
5. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science*. 2020 Oct 23; 370(6515):eabd4585. doi: 10.1126/science.abd4585. Epub 2020 Sep 24. PMID: 32972996.
6. Poulas K, Farsalinos K, Zanidis C. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy. *Front Immunol*. 2020 Jun 11;11:1373. doi: 10.3389/fimmu.2020.01373. PMID: 32612613; PMCID: PMC7307572.
7. Mele D, Mantovani S, Oliviero B, Grossi G, Ludovisi S, Mondelli MU, et al. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. *Antiviral Res*. 137, 108-111 (2017).

8. van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19 [published online ahead of print, 2020 Jul 24]. *JAMA*. 324, 1-11 (2020).
9. Daga S, Fallerini C, Baldassarri M, Fava F, Valentino F, Doddato G, et al. Employing a Systematic Approach to Biobanking and Analyzing Genetic and Clinical Data for Advancing COVID-19 Research. *medRxiv* 2020.07.24.20161307; doi: <https://doi.org/10.1101/2020.07.24.20161307> (2020).

## TABLES

**Table 1.** Fisher exact test of the overall combined cohorts in young males (<60 years).

Clinical Category	N. Wild Type patients	N. Mutated patients	Total
Severely Affected Males	150	6	156
Asymptomatic Males	122	0	122
<b>Total</b>	272	6	278 (Grand Total)
p-value = 0.04			

**Table 2A.** *TLR7* mutations in severely affected Italian and Spanish males -all ages- (cases).

Nucleotide change	Amino acid change	dbSNP	CADD	ExAC_NFE	Clinical Category*	Age	Cohort	Patient ID
c.655G>A	Val219Ile	rs149314023	12.28	0.0003	4	32	Italian	P1
c.863C>T	Ala288Val	rs200146658	15.37	0	3	57	Italian	P2
c.901T>C	Ser301Pro	-	26.4	N/A	3	46	Italian	P3
c.1343C>T	Ala448Val	rs5743781	13.08	0.0047	3	53	Italian	P4
c.1343C>T	Ala448Val	rs5743781	13.08	0.0047	3	58	Italian	P5
c.1888C>T	His630Tyr	-	19.16	0	4	50	Spanish	P6
c.3094G>A	Ala1032Thr	rs147244662	22.3	0.0006	3	65	Italian	P7
c.3094G>A	Ala1032Thr	rs147244662	22.3	0.0006	3	66	Italian	P8

**Table 2B.** *TLR7* mutations in asymptomatic males (controls).

Nucleotide change	Amino acid change	dbSNP	CADD	ExAC_NFE	Clinical Category	Age	Cohort	Patient ID
c.665T>A	Val222Asp	rs5590784 3	5.36	0.0047	0	64	Italian	C1

\*Clinical categories: **4.** Hospitalized and intubated patients; **3.** Hospitalized and CPAP-BiPAP and high-flows oxygen treated; **2.** Hospitalized and treated with conventional oxygen support only; **1.** Hospitalized without respiratory support; **0.** Not hospitalized oligo/asymptomatic individuals

## FIGURE LEGENDS

**Figure 1. Rare *TLR7* variants and association with COVID-19.** LASSO logistic regression on boolean representation of rare variants of all genes of the X chromosome (X chr). *TLR7* is picked up by LASSO logistic regression as one of the most important genes on the X chr (**Panel A**). The LASSO logistic regression model provides an embedded feature selection method within the binary classification tasks (male patients with life-threatening COVID-19 vs infected asymptomatic male subjects). The upward histograms (positive weights) reflect a susceptible behaviour of the features to the target COVID-19, whereas the downward histograms (negative weights) a protective action. In addition to the *TLR7* gene, other genes are picked up, including *XPNPEP2* dysregulation bradykinine system. **Panel B** represents the cross-validation accuracy score for the grid of LASSO regularization parameters; the error bar is given by the standard deviation of the score within the 10 folds; the red point (1.26) corresponds to the parameter chosen for the fitting procedure. Performances are evaluated through the confusion matrix of the aggregated predictions in the 10 folds of the cross-validation (**Panel C**) and with the boxplot (**Panel D**) of accuracy (60% average value), precision (59%), sensitivity (75%), specificity (43%), and ROC-AUC score (68%). The box extends from the Q1 to Q3 quartile, with a line at the median (Q2) and a triangle for the average.

**Figure 2. Gene expression profile analysis in peripheral blood mononuclear cells (PBMCs) after stimulation with a *TLR7* agonist for 4 hours.**  $5 \times 10^5$  PBMCs from COVID-19 patients and four unaffected male and female controls were stimulated for 4 hours with the *TLR7* agonist imiquimod at 5  $\mu\text{g/mL}$  or cell culture medium. Quantitative PCR assay was performed and the  $2^{-\Delta\Delta C_t}$  calculated using *HPRT1* as housekeeping gene. Fold change in mRNA expression of *TLR7* and type 1 IFN-related genes *ISG15*, *IRF7*, *IFN- $\alpha$*  and *IFN- $\gamma$*  induced by *TLR7* agonist imiquimod was compared with cell culture medium. Error bars show standard deviations. *P* values were calculated using an unpaired *t* test: \**P* < .05; \*\**P* < .01; \*\*\**P* < .001; \*\*\*\**P* < .0001. Ctl indicates

healthy controls; C<sub>1</sub>, the asymptomatic mutated control; P1, P3, P8, P6, P7 severely affected mutated cases (as in **Table 2A**).

**Figure 3. Segregation analysis in Italian (P3) and Spanish family (P6).** Fold change in mRNA expression of the main *TLR7*-effector, *IRF7*, is shown in **Panel A**. Pedigree (**Panel B**) and respective segregation of *TLR7* variant and COVID-19 status (**Panel C**). Squares represent male family members; circles, females.

## ADDITIONAL INFORMATION

### GEN-COVID Multicenter Study (<https://sites.google.com/dbm.unisi.it/gen-covid>)

Floriana Valentino<sup>1,2</sup>, Gabriella Doddato<sup>1,2</sup>, Annarita Giliberti<sup>1,2</sup>, Rossella Tita<sup>9</sup>, Sara Amitrano<sup>9</sup>, Mirella Bruttini<sup>1,2,9</sup>, Susanna Croci<sup>1,2</sup>, Ilaria Meloni<sup>1,2</sup>, Maria Antonietta Mencarelli<sup>9</sup>, Caterina Lo Rizzo<sup>9</sup>, Anna Maria Pinto<sup>9</sup>, Laura Di Sarno<sup>1,2</sup>, Giada Beligni<sup>1,2</sup>, Andrea Tommasi<sup>1,2,9</sup>, Maria Palmieri<sup>1,2</sup>, Francesca Montagnani<sup>2,17</sup>, Arianna Emiliozzi<sup>2,17</sup>, Massimiliano Fabbiani<sup>17</sup>, Barbara Rossetti<sup>17</sup>, Giacomo Zanelli<sup>2,17</sup>, Elena Bargagli<sup>18</sup>, Laura Bergantini<sup>18</sup>, Miriana D'Alessandro<sup>18</sup>, Paolo Cameli<sup>18</sup>, David Bennet<sup>18</sup>, Federico Anedda<sup>19</sup>, Simona Marcantonio<sup>19</sup>, Sabino Scolletta<sup>19</sup>, Federico Franchi<sup>19</sup>, Maria Antonietta Mazzei<sup>20</sup>, Susanna Guerrini<sup>20</sup>, Edoardo Conticini<sup>21</sup>, Luca Cantarini<sup>21</sup>, Bruno Frediani<sup>21</sup>, Danilo Tacconi<sup>22</sup>, Chiara Spertilli<sup>22</sup>, Marco Feri<sup>23</sup>, Alice Donati<sup>23</sup>, Raffaele Scala<sup>24</sup>, Luca Guidelli<sup>24</sup>, Genni Spargi<sup>25</sup>, Marta Corridi<sup>25</sup>, Cesira Nencioni<sup>26</sup>, Leonardo Croci<sup>26</sup>, Gian Piero Caldarelli<sup>27</sup>, Maurizio Spagnesi<sup>16</sup>, Paolo Piacentini<sup>16</sup>, Elena Desantis<sup>16</sup>, Silvia Cappelli<sup>16</sup>, Anna Canaccini<sup>28</sup>, Agnese Verzuri<sup>28</sup>, Valentina Anemoli<sup>28</sup>, Agostino Ognibene<sup>29</sup>, Antonella D'Arminio Monforte<sup>30</sup>, Esther Merlini<sup>30</sup>, Federica Gaia Miraglia<sup>30</sup>, Massimo Girardis<sup>31</sup>, Sophie Venturelli<sup>31</sup>, Marco Sita<sup>31</sup>, Andrea Cossarizza<sup>32</sup>, Andrea Antinori<sup>33</sup>, Alessandra Vergori<sup>33</sup>, Arianna Gabrieli<sup>15</sup>, Agostino Riva<sup>14,15</sup>, Daniela Francisci<sup>34,35</sup>, Elisabetta Schiaroli<sup>34</sup>, Pier Giorgio Scotton<sup>36</sup>, Francesca Andretta<sup>36</sup>, Sandro Panese<sup>37</sup>, Renzo Scaggiante<sup>38</sup>, Francesca Gatti<sup>38</sup>, Saverio Giuseppe Parisi<sup>39</sup>, Stefano Baratti<sup>39</sup>, Melania Degli Antoni<sup>12</sup>, Isabella Zanella<sup>12</sup>, Matteo Della Monica<sup>40</sup>, Carmelo Piscopo<sup>40</sup>, Mario Capasso<sup>41,42,43</sup>, Roberta Russo<sup>41,42</sup>, Immacolata Andolfo<sup>41,42</sup>, Achille Iolascon<sup>41,42</sup>, Giuseppe Fiorentino<sup>44</sup>, Massimo Carella<sup>45</sup>, Marco Castori<sup>45</sup>, Giuseppe Merla<sup>45</sup>, Filippo Aucella<sup>46</sup>, Pamela Raggi<sup>47</sup>, Carmen Marciano<sup>47</sup>, Rita Perna<sup>47</sup>, Matteo Bassetti<sup>48,49</sup>, Antonio Di Biagio<sup>49</sup>, Maurizio Sanguinetti<sup>50,51</sup>, Luca Masucci<sup>50,51</sup>, Serafina Valente<sup>52</sup>, Marco Mandalà<sup>53</sup>, Alessia Giorli<sup>53</sup>, Lorenzo Salerni<sup>53</sup>, Patrizia Zucchi<sup>54</sup>, Pierpaolo Parravicini<sup>54</sup>, Elisabetta Menatti<sup>55</sup>, Tullio Trotta<sup>56</sup>, Ferdinando Giannattasio<sup>56</sup>, Gabriella Coiro<sup>56</sup>, Fabio Lena<sup>57</sup>, Domenico A. Coviello<sup>58</sup>, Cristina Mussini<sup>59</sup>, Giancarlo Bosio<sup>60</sup>, Enrico Martinelli<sup>60</sup>, Sandro Mancarella<sup>61</sup>, Luisa Tavecchia<sup>61</sup>, Marco Gori<sup>8,6</sup>, Lia Crotti<sup>63,64,65,66</sup>, Agatha Schluter<sup>4,5,67</sup>, Laura Planas-Serra<sup>4,5,67</sup>, Marta Gut<sup>68</sup>, Chiara Gabbi<sup>69</sup>.


- 17) Dept of Specialized and Internal Medicine, Tropical and Infectious Diseases Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- 18) Unit of Respiratory Diseases and Lung Transplantation, Department of Internal and Specialist Medicine, University of Siena, Italy
- 19) Dept of Emergency and Urgency, Medicine, Surgery and Neurosciences, Unit of Intensive Care Medicine, Siena University Hospital, Italy
- 20) Department of Medical, Surgical and Neuro Sciences and Radiological Sciences, Unit of Diagnostic Imaging, University of Siena, Italy
- 21) Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Italy
- 22) Department of Specialized and Internal Medicine, Infectious Diseases Unit, San Donato Hospital Arezzo, Italy
- 23) Dept of Emergency, Anesthesia Unit, San Donato Hospital, Arezzo, Italy
- 24) Department of Specialized and Internal Medicine, Pneumology Unit and UTIP, San Donato Hospital, Arezzo, Italy
- 25) Department of Emergency, Anesthesia Unit, Misericordia Hospital, Grosseto, Italy

- 26) Department of Specialized and Internal Medicine, Infectious Diseases Unit, Misericordia Hospital, Grosseto, Italy
- 27) Clinical Chemical Analysis Laboratory, Misericordia Hospital, Grosseto, Italy
- 28) Territorial Scientific Technician Department, Azienda USL Toscana Sud Est, Italy
- 29) Clinical Chemical Analysis Laboratory, San Donato Hospital, Arezzo, Italy
- 30) Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Italy
- 31) Department of Anesthesia and Intensive Care, University of Modena and Reggio Emilia, Modena, Italy
- 32) Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
- 33) HIV/AIDS Department, National Institute for Infectious Diseases, IRCCS, Lazzaro Spallanzani, Rome, Italy
- 34) Infectious Diseases Clinic, Department of Medicine 2, Azienda Ospedaliera di Perugia and University of Perugia, Santa Maria Hospital, Perugia, Italy
- 35) Infectious Diseases Clinic, "Santa Maria" Hospital, University of Perugia, Perugia, Italy
- 36) Department of Infectious Diseases, Treviso Hospital, Local Health Unit 2 Marca Trevigiana, Treviso, Italy
- 37) Clinical Infectious Diseases, Mestre Hospital, Venezia, Italy
- 38) Infectious Diseases Clinic, ULSS1, Belluno, Italy
- 39) Department of Molecular Medicine, University of Padova, Italy
- 40) Medical Genetics and Laboratory of Medical Genetics Unit, A.O.R.N. "Antonio Cardarelli", Naples, Italy
- 41) Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy
- 42) CEINGE Biotechnologie Avanzate, Naples, Italy
- 43) IRCCS SDN, Naples, Italy
- 44) Unit of Respiratory Physiopathology, AORN dei Colli, Monaldi Hospital, Naples, Italy
- 45) Division of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
- 46) Department of Medical Sciences, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
- 47) Clinical Trial Office, Fondazione IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
- 48) Department of Health Sciences, University of Genova, Genova, Italy
- 49) Infectious Diseases Clinic, Policlinico San Martino Hospital, IRCCS for Cancer Research Genova, Italy
- 50) Microbiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of Medicine, Rome, Italy
- 51) Department of Laboratory Sciences and Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 52) Department of Cardiovascular Diseases, University of Siena, Siena, Italy
- 53) Otolaryngology Unit, University of Siena, Italy
- 54) Department of Internal Medicine, ASST Valtellina e Alto Lario, Sondrio, Italy
- 55) Study Coordinator Oncologia Medica e Ufficio Flussi Sondrio, Italy
- 56) First Aid Department, Luigi Curto Hospital, Polla, Salerno, Italy
- 57) Local Health Unit-Pharmaceutical Department of Grosseto, Toscana Sud Est Local Health Unit, Grosseto, Italy
- 58) U.O.C. Laboratorio di Genetica Umana, IRCCS Istituto G. Gaslini, Genova, Italy
- 59) Infectious Diseases Clinics, University of Modena and Reggio Emilia, Modena, Italy
- 60) Department of Respiratory Diseases, Azienda Ospedaliera di Cremona, Cremona, Italy
- 61) U.O.C. Medicina, ASST Nord Milano, Ospedale Bassini, Cinisello Balsamo (MI), Italy
- 62) Université Côte d'Azur, Inria, CNRS, I3S, Maasai
- 63) Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy
- 64) Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy




- 65) Istituto Auxologico Italiano, IRCCS, Center for Cardiac Arrhythmias of Genetic Origin, Milan, Italy
- 66) Istituto Auxologico Italiano, IRCCS, Laboratory of Cardiovascular Genetics, Milan, Italy
- 67) Spanish Covid HGE
- 68) CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Carrer Baldiri i Reixac 4, 08028, Barcelona, Spain.
- 69) Independent Scientist, Milan, Italy


A



B



C



D

